Histology
Large Cell Carcinoma
CI-CAN-00001061Explore in graph →
47 active trials2 approved drugs5 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001061Explore in graph →
Clinical trials
159 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (30)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04458909 | Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer | terminated | Phase 3 | 15 | National Cancer Institute (NCI)NIH | 4 | Oct 3, 2025 | clinicaltrials |
| NCT00946712 | S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer | terminated | Phase 3 | 1,333 | SWOG Cancer Research NetworkNETWORK |
| 2 |
| May 23, 2023 |
| clinicaltrials |
| NCT00507429 | Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer(FACT) | terminated | Phase 2 / Phase 3 | 80 | Mateon TherapeuticsINDUSTRY | 12 | Jun 9, 2014 | clinicaltrials |
| NCT00596830 | Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology | terminated | Phase 3 | 681 | PfizerINDUSTRY | 26 | Jan 13, 2014 | clinicaltrials |
| NCT00673049 | Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer(NSCLC) | terminated | Phase 3 | 583 | PfizerINDUSTRY | 27 | Jul 24, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Oct 3, 2025source: clinicaltrials